Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is largely ineffective. Therefore, new therapeut...
Main Authors: | Md Sazzad Hassan, Niranjan Awasthi, Jun Li, Fiona Williams, Margaret A. Schwarz, Roderich E. Schwarz, Urs von Holzen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-04-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523317304394 |
Similar Items
-
Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.
by: Changhua Zhang, et al.
Published: (2013-01-01) -
A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma.
by: Md Sazzad Hassan, et al.
Published: (2017-01-01) -
Albumin-bound paclitaxel in the treatment of metastatic breast cancer
by: E V Artamonova
Published: (2017-01-01) -
Nanoparticle Albumin-Bound-Paclitaxel in the Treatment of Metastatic Urethral Adenocarcinoma: The Significance of Molecular Profiling and Targeted Therapy
by: Yasmin M. Abaza, et al.
Published: (2014-01-01) -
Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
by: Zhichao Tian, et al.
Published: (2020-07-01)